Alterity Therapeutics Limited (ATHE) Earnings History
Net Loss24 years of earnings data (2002–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Alterity Therapeutics Limited (ATHE) Earnings Overview
As of June 28, 2026, Alterity Therapeutics Limited (ATHE) reported trailing twelve-month net income of -$34M, reflecting +63.5% year-over-year growth. The company earned $-2.02 per diluted share over the past four quarters, with a net profit margin of -223.4%.
Looking at the long-term picture, ATHE's historical earnings data spans multiple years. The company achieved its highest annual net income of -$5M in fiscal 2003.
Alterity Therapeutics Limited is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including PRTA (-$151M net income, -2520.6% margin), ACAD ($376M net income, 36.5% margin), SAVA (-$106M net income), ATHE has outperformed on profitability metrics. Compare ATHE vs PRTA →
ATHE Earnings vs Peers
Earnings metrics vs comparable public companies
ATHE Historical Earnings Data (2002–2025)
24 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$12M | +36.5% | -$15M | $-1.14 | -223.4% | -268.0% |
| 2024 | -$19M | -38.5% | -$20M | $-3.12 | -475.8% | -487.7% |
| 2023 | -$14M | -7.5% | -$15M | $-3.42 | -352.5% | -373.7% |
| 2022 | -$13M | +16.1% | -$16M | $-3.18 | -250.7% | -302.6% |
| 2021 | -$15M | -52.2% | -$15M | $-5.40 | -352.8% | -349.8% |
| 2020 | -$10M | +15.9% | -$10M | $-6.48 | - | - |
| 2019 | -$12M | -44.7% | -$13M | $-11.64 | -11020.8% | -11713.7% |
| 2018 | -$8M | -9.6% | -$8M | $-9.30 | -4108.8% | -3862.5% |
| 2017 | -$8M | +2.4% | -$7M | $-8.46 | -5696.6% | -5197.9% |
| 2016 | -$8M | -31.3% | -$9M | $-8.70 | -5418.3% | -6019.2% |
| 2015 | -$6M | +55.8% | -$10M | $-7.02 | -3327.9% | -5901.1% |
| 2014 | -$13M | -71.2% | -$13M | $-18.66 | -3664.1% | -3450.6% |
| 2013 | -$8M | -48.6% | -$8M | $-13.80 | -5161.7% | -5171.4% |
| 2012 | -$5M | +18.5% | -$5M | $-10.92 | -2806.9% | -2849.3% |
| 2011 | -$6M | -31.1% | -$6M | $-15.60 | -4119.0% | -4020.2% |
| 2010 | -$5M | +34.8% | -$5M | $-12.96 | -2282.2% | -2279.4% |
| 2009 | -$8M | +44.6% | -$8M | $-22.32 | -1756.9% | -1935.7% |
| 2008 | -$14M | -22.0% | -$13M | $-46.68 | -2762.2% | -2588.2% |
| 2007 | -$11M | +5.0% | -$11M | $-47.46 | -2197.0% | -2167.6% |
| 2006 | -$12M | +52.9% | -$11M | $-54.96 | -1537.9% | -1496.9% |
| 2005 | -$25M | -153.5% | -$12M | $-120.00 | -942.6% | -446.9% |
| 2004 | -$10M | -114.9% | -$9M | $-78.00 | -425.9% | -385.3% |
| 2003 | -$5M | +16.1% | -$4M | $-47.76 | -252.4% | -209.4% |
| 2002 | -$5M | - | -$5M | $-59.82 | -686.2% | -628.9% |
Download Data
Export ATHE earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
24+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ATHE — Frequently Asked Questions
Quick answers to the most common questions about buying ATHE stock.
What is ATHE earnings per share (EPS)?
ATHE trailing twelve-month (TTM) diluted EPS is $-2.02, reflecting +63.5% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2002 to 2025 is available in the table on this page.
What is Alterity Therapeutics Limited's net income?
Alterity Therapeutics Limited (ATHE) trailing twelve-month net income is $-34M as of 2025. Earnings grew +63.5% year-over-year.
Is ATHE profitable?
ATHE is not currently profitable on a TTM basis, reporting a net loss of $-34M. Net margin is -223.4%. Investors should monitor for a return to profitability.
What is ATHE's earnings growth rate?
ATHE compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2002 to 2025.
What are ATHE's profit margins?
Alterity Therapeutics Limited net profit margin is -223.4%, operating margin is -268.0%, and gross margin is +97.7%. Below-average margins reflect competitive or cost pressures. Return on Equity is -43.2%.
Is ATHE growing earnings?
Yes, ATHE earnings are accelerating — EPS growth of +63.5% exceeds the 5-year CAGR of N/A. TTM net income reached $-34M. Earnings momentum is strengthening.
What was ATHE's best earnings year?
Alterity Therapeutics Limited's highest annual net income on record is $-5M, achieved in fiscal year 2003. Earnings history on this page spans 2002 to 2025 and includes all annual and quarterly figures.
What were ATHE's earnings last quarter?
ATHE's most recent reported quarter was Q2 2026. Net income was $-9M with diluted EPS of $-0.54. For a full breakdown of all quarters, see the quarterly earnings table on this page.